Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain due to vascular smooth muscle spasm

A technology for vascular smooth muscle and fibromyalgia, which is used in cardiovascular system diseases, non-central analgesics, anti-inflammatory agents, etc., to achieve the effect of inhibiting thrombosis

Inactive Publication Date: 2011-01-05
森重福美
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, for the use of compositions containing RNA, L-arginine and L-ascorbic acid for the treatment of fibromyalgia syndrome belonging to the classification of chronic pain, there is also no report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain due to vascular smooth muscle spasm
  • Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain due to vascular smooth muscle spasm

Examples

Experimental program
Comparison scheme
Effect test

manufacture example 1

[0122] Production Example 1. Production of RNA

[0123] (1) Slurry yeast recovered from the beer manufacturing process was passed through a sieve of 80 to 200 meshes to remove solid content, washed with 0.5% to 1% aqueous sodium carbonate solution, and washed with water to obtain debittering yeast.

[0124] (2) Add salt and water so that the yeast concentration is 10%, and the salt concentration is 10%, heat up and boil for 2 to 5 hours. The boiling conditions can be replaced by autoclaving for 1 hour.

[0125] (3) Extract ribonucleic acid under boiling, then cool, and perform solid-liquid separation with a centrifuge or the like to obtain an extract. The RNA remaining in the solid fraction was washed with 10% saline, and the washed solution was recovered and combined with the previous extraction solution.

[0126] (4) Concentrated hydrochloric acid was added to the extract to adjust the pH to 2 to obtain a fraction that precipitated under acidic conditions. The precipitate...

manufacture example 2

[0127] Production Example 2. Production of RNA

[0128] Add 450L of water to 90kg of dry beer yeast and stir for a certain period of time to dissolve the inclusions and wash the yeast. Next, centrifugation was performed to recover the washed yeast, and 800 L of water and 90 kg of salt were added for heating. Boil for 2 hours, and then use a centrifuge to obtain an extract. For the ribonucleic acid remaining in the residue, add 10% saline, and recover the washing solution. The extracts were pooled and subjected to the same treatment as in (4) and subsequent steps of RNA Production Example 1 to obtain brewer's yeast crude RNA.

manufacture example 3

[0129] Production Example 3. Production of RNA

[0130] The pulpy brewer's yeast is subjected to debittering washing by a conventional method, and dried with a drum dryer at 120-140°C. 10 times the amount of hot water above 95° C. was added to the dry beer yeast, kept for 5 minutes, and then solid-liquid separation was performed to obtain a solid substance. Add salt and water to the solid matter, adjust the concentration of beer yeast solid matter to 10%, and the concentration of salt to 10%. In order to break the cell wall, put it into a homogenizer so that the ejection pressure is 600kg / cm 2 above. The treatment solution containing the crushed yeast was heated and boiled for 2 to 5 hours, and the same treatment as that in (3) and subsequent steps of RNA production example 1 was performed to obtain brewer's yeast crude RNA.

[0131] The following table shows the compositional analysis results of the crude RNA obtained in these production examples.

[0132] [Table 2]

[01...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are a therapeutic agent for fibromyalgia syndrome and a therapeutic agent for pain due to vascular smooth muscle spasm. The therapeutic agent for fibromyalgia syndrome or therapeutic agent for pain due to vascular smooth muscle spasm containing a) one or more compounds selected from the group consisting of RNA, ribonucleotides and ribonucleosides; b) one or more compounds selected from the group consisting of L-arginine, L-citrulline and L-ornithine; and c) L-ascorbic acid, wherein a mass ratio of the component b) to component c) is 1:0.2 to 20.

Description

technical field [0001] The present invention relates to a therapeutic agent for fibromyalgia syndrome and a therapeutic agent for pain caused by vascular smooth muscle spasm, the therapeutic agent for fibromyalgia syndrome comprising (a) One or more compounds (hereinafter referred to as RNA, etc.), (b) one or more compounds selected from L-arginine, L-citrulline, and L-ornithine, and (c) L-ascorbic acid (hereinafter (referred to as ascorbic acid), wherein the mass ratio of component (b):component (c) is 1:0.2-20, especially 0.2-0.25. Background technique [0002] Chronic pain generally refers to a broad term defined as pain that lasts longer than acute disease or lasts longer than the time corresponding to the injury should heal, or recurs at intervals of months or years. Chronic pain can have a variety of symptoms, such as musculoskeletal or spinal pain, neuropathic pain, headache, or vascular pain. [0003] Fibromyalgia syndrome (hereinafter, sometimes abbreviated as FMS...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/711A61K31/198A61K31/375A61P21/00
CPCA61K31/375A61K9/14A61K31/198A61K36/064A61P21/00A61P25/00A61P29/00A61P9/00A61K2300/00
Inventor 森重福美
Owner 森重福美
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com